Clinical inquiries. Are ARBs or ACE inhibitors preferred for nephropathy in diabetes?
Foreman
Brett H
BH
Moses Cone Health System, Greensboro, NC, USA.
Chambliss
M Lee
ML
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000401:mortality; D004311:Double-Blind Method; D006801:Humans; D000077405:Irbesartan; D019808:Losartan / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D013777:Tetrazoles / Q000627:therapeutic use
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D001713:Biphenyl Compounds; D013777:Tetrazoles; D000077405:Irbesartan; D019808:Losartan